GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2008

ArQule Receives $3M Milestone from Kyowa for Initiation of Oncology Trial

  • ArQule received a $3 million milestone payment from Kyowa Hakko Kogyo. The fee was triggered by Kyowa’s initiation of a Phase I dose-escalation trial in Japan with ArQule’s lead anticancer agent. ARQ 197 is a small molecule, selective inhibitor of the c-Met receptor tyrosine kinase.

    This payment was made under the terms of a license agreement inked in April 2007. It includes $123 million in upfront and potential development milestone payments from Kyowa, of which ArQule previously received a $30 million cash licensing fee. The agreement also includes sales milestone payments and provides double-digit royalties on net sales in certain Asian countries. Kyowa is responsible for clinical development costs and commercialization in these regions.

    ArQule retains rights to ARQ 197 in the rest of the world. In the U.S., the company has initiated a Phase II program with this compound that includes ongoing trials in microphthalmia transcription factor-driven pediatric tumors and pancreatic cancer.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?